CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Locally Recurrent Colorectal Cancer
Clinical trial NCT06881537 · RECRUITING
Trial details
- NCT number
- NCT06881537
- Sponsor
- Shanghai Changzheng Hospital
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-06-01
- Primary completion
- 2025-06-30
- Enrollment
- 15
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.